You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(00867.HK)強烈否認殺人鯨資本指控 周一復牌
阿思達克 02-09 09:23

康哲藥業(00867.HK)聲明,強烈否認殺人鯨資本提出針對公司之各項指控,認為該等指控毫無根據且具嚴重誤導性,並就指控反駁,其中主要包括︰

公司自上市以來,財務報表均由國際四大會計師事務所審核,並出具無保留意見審計報告。公司於年度報告中披露關於利潤的財務資料匯總了國際業務和國內業務利潤,而殺人鯨資本於該報告中僅統計了集團國內業務涉及的兩個主要子公司之利潤,並未統計國際業務子公司利潤,妄下判斷該兩間子公司代表了整個集團的業務;

馬來西亞公司國際貿易是真實存在的,出於運營效率和成本節約考慮,進口產品實物未經過馬來西亞,而由集團從海外生產廠家直接發貨到香港或中國,這是國際轉口貿易常態;

公司在香港上市前,將其研發業務分拆到康哲研究,康哲研究的股東除了主席外還有其他股東。分拆時CMS024項目的相關權利屬公司,後續研究費用由康哲研究承擔,公司並無秘密支付本應由A&B(即主席之私人公司)承擔的研發費用;及CMS024成功商業化後公司向康哲研究支付13%專利費。

公司股份申請周一(10日)恢復買賣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account